-
Contains 16 practice-oriented topics including fibroblast activation protein inhibitor (FAPI) PET imaging in pancreatic cancer; fibroblast activation protein inhibitor (FAPI) PET imaging in colorectal cancer; fibroblast activation protein inhibitor (FAPI) cardiac imaging; fibroblast activation protein inhibitor (FAPI) PET/CT in gastric cancer; and more.�
-
Provides in-depth clinical reviews on fibroblast activation protein imaging, offering actionable insights for clinical practice.�
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.�
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Advanced Fibroblast Activation Protein-Ligand Developments: FAP Imaging Agents: A Review of the Structural Requirements
Fibroblast Activation Protein Inhibitor PET in Pancreatic Cancer
The Diagnostic Value of Fibroblast Activation Protein Imaging in Hepatocellular Carcinoma and Cholangiocellular Carcinoma
Fibroblast Activation Protein Inhibitor PET Imaging in Head and Neck Cancer
Fibroblast Activation Protein Inhibitor-PET Imaging in Colorectal Cancer
Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer
Current Status of Fibroblast Activation Protein Imaging in Gynecologic Malignancy and Breast Cancer
Fibroblast Activation Protein Inhibitor (FAPI)-PET Imaging in Sarcoma
Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma
Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor
Imaging Fibrosis
Cardiac Applications of Fibroblast Activation Protein Imaging
Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations
Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment
Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation
Current State of Clinical Trials and Regulatory Approvals with Fibroblast Activation Protein Targeting Interventions
